Columbia Laboratories (CBRX) 5.78 $CBRX
Columbia Laboratories' Management Presents at 17th Annual BIO CEO & Investor Conference (Transcript)
SA Transcripts - at Seeking Alpha - Mon Feb 09, 2:50PM CST
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Date of 2015 Annual Meeting of Stockholders
PR Newswire - Thu Feb 05, 4:01PM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that its annual meeting of stockholders will be held on June 2, 2015. The Company will announce the time and location of the meeting at a later date.
CBRX: 5.78 (+0.09)
Columbia Laboratories to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:30AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that it will present at the upcoming 17th Annual BIO CEO & Investor Conference, to be held at the Waldorf Astoria in New York City. Columbia's CEO, Frank Condella, will present at the conference at 1:00pm on February 9th in the Duke of Windsor room.
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Search For New Board Member, Impending Retirement of Chairman Stephen G. Kasnet; Amendment to Increase Permissible Ownership Levels Under Shareholder Rights Plan
PR Newswire - Thu Jan 29, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that the Company's Chairman, Stephen G. Kasnet, has informed the Company that he does not intend to stand for reelection to the Board of Directors when his current term expires at the next annual shareholder meeting, which is expected to be held in May, 2015.
CBRX: 5.78 (+0.09)
Columbia Laboratories names Dr. Bridget A. Martell as CMO
M2 - Wed Jan 07, 6:32AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) announced on Tuesday the addition of Dr. Bridget A. Martell as its chief medical officer.
CBRX: 5.78 (+0.09)
New medical chief at Columbia Labs
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 10:37AM CST
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Appointment of Chief Medical Officer
PR Newswire - Tue Jan 06, 7:00AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced the appointment of Dr. Bridget A. Martell, 49, to the newly created position of Chief Medical Officer, effective immediately. The appointment is an important step in Columbia's focus on advancing a proprietary drug program. The Company expects to advance its next product candidate COL-1077, an extended release lidocaine gel for the treatment of gynecological procedure related pain, into clinical trials this year. Columbia continues to receive product revenue and royalties from its initial commercial product, Crinone ®, a vaginal progesterone gel used in fertility treatment.
CBRX: 5.78 (+0.09)
OTC Daily Alert Stock Watch - Columbia Laboratories, Inc (NASDAQ: CBRX)
WorldStockWire - Mon Dec 29, 3:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CBRX: 5.78 (+0.09)
Molecular Profiles To Launch US Strategic Alliance At AAPS
PR Newswire - Thu Oct 30, 7:30AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launched at AAPS in San Diego next week.
CBRX: 5.78 (+0.09)
Columbia Laboratories achieves higher Q3 2014 net income of USD3.7m
M2 - Wed Oct 29, 4:48AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) on Tuesday reported that its net income was USD3.7m, or USD0.34 per diluted share, for the three month periods ended 30 September 2014.
CBRX: 5.78 (+0.09)
Columbia Laboratories' (CBRX) CEO Frank Condella on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:39PM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 1:05PM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories EPS of $0.34
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:18AM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" today announced financial results for the three and nine-month periods ended September 30, 2014.
CBRX: 5.78 (+0.09)
Columbia Labs reports on October 28
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:17AM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories to Discuss Third Quarter 2014 Financial Results on October 28th Conference Call
PR Newswire - Tue Oct 14, 11:51AM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28th, 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows:
CBRX: 5.78 (+0.09)
Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI
PR Newswire - Wed Oct 01, 7:30AM CDT
Columbia Laboratories, Inc., (Nasdaq: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to support companies with the rapid development of both standard and complex drug products.
CBRX: 5.78 (+0.09)
Columbia Laboratories announces George O. Elston as its new CFO
M2 - Thu Sep 25, 7:30AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Wednesday that its board has appointed George O. Elston as its chief financial officer.
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Appointment of New Chief Financial Officer
PR Newswire - Wed Sep 24, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company" , a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that the Board has named George O. Elston, 50, as Chief Financial Officer, effective October 1. He succeeds Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities.
CBRX: 5.78 (+0.09)
Columbia Laboratories' Management Presents at 17th Annual BIO CEO & Investor Conference (Transcript)
SA Transcripts - at Seeking Alpha - Mon Feb 09, 2:50PM CST
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Date of 2015 Annual Meeting of Stockholders
PR Newswire - Thu Feb 05, 4:01PM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that its annual meeting of stockholders will be held on June 2, 2015. The Company will announce the time and location of the meeting at a later date. CBRX: 5.78 (+0.09)
Columbia Laboratories to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:30AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that it will present at the upcoming 17th Annual BIO CEO & Investor Conference, to be held at the Waldorf Astoria in New York City. Columbia's CEO, Frank Condella, will present at the conference at 1:00pm on February 9th in the Duke of Windsor room. CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Search For New Board Member, Impending Retirement of Chairman Stephen G. Kasnet; Amendment to Increase Permissible Ownership Levels Under Shareholder Rights Plan
PR Newswire - Thu Jan 29, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced that the Company's Chairman, Stephen G. Kasnet, has informed the Company that he does not intend to stand for reelection to the Board of Directors when his current term expires at the next annual shareholder meeting, which is expected to be held in May, 2015. CBRX: 5.78 (+0.09)
Columbia Laboratories names Dr. Bridget A. Martell as CMO
M2 - Wed Jan 07, 6:32AM CST
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) announced on Tuesday the addition of Dr. Bridget A. Martell as its chief medical officer.
CBRX: 5.78 (+0.09)
New medical chief at Columbia Labs
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 10:37AM CST
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Appointment of Chief Medical Officer
PR Newswire - Tue Jan 06, 7:00AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a specialty pharmaceutical company focused on pharmaceuticals for women's health, today announced the appointment of Dr. Bridget A. Martell, 49, to the newly created position of Chief Medical Officer, effective immediately. The appointment is an important step in Columbia's focus on advancing a proprietary drug program. The Company expects to advance its next product candidate COL-1077, an extended release lidocaine gel for the treatment of gynecological procedure related pain, into clinical trials this year. Columbia continues to receive product revenue and royalties from its initial commercial product, Crinone ®, a vaginal progesterone gel used in fertility treatment. CBRX: 5.78 (+0.09)
OTC Daily Alert Stock Watch - Columbia Laboratories, Inc (NASDAQ: CBRX)
WorldStockWire - Mon Dec 29, 3:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CBRX: 5.78 (+0.09)
Molecular Profiles To Launch US Strategic Alliance At AAPS
PR Newswire - Thu Oct 30, 7:30AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launched at AAPS in San Diego next week.
CBRX: 5.78 (+0.09)
Columbia Laboratories achieves higher Q3 2014 net income of USD3.7m
M2 - Wed Oct 29, 4:48AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) on Tuesday reported that its net income was USD3.7m, or USD0.34 per diluted share, for the three month periods ended 30 September 2014.
CBRX: 5.78 (+0.09)
Columbia Laboratories' (CBRX) CEO Frank Condella on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:39PM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 1:05PM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories EPS of $0.34
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:18AM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
today announced financial results for the three and nine-month periods ended September 30, 2014. CBRX: 5.78 (+0.09)
Columbia Labs reports on October 28
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:17AM CDT
CBRX: 5.78 (+0.09)
Columbia Laboratories to Discuss Third Quarter 2014 Financial Results on October 28th Conference Call
PR Newswire - Tue Oct 14, 11:51AM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28th, 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows:
CBRX: 5.78 (+0.09)
Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI
PR Newswire - Wed Oct 01, 7:30AM CDT
Columbia Laboratories, Inc., (Nasdaq: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to support companies with the rapid development of both standard and complex drug products.
CBRX: 5.78 (+0.09)
Columbia Laboratories announces George O. Elston as its new CFO
M2 - Thu Sep 25, 7:30AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Wednesday that its board has appointed George O. Elston as its chief financial officer.
CBRX: 5.78 (+0.09)
Columbia Laboratories Announces Appointment of New Chief Financial Officer
PR Newswire - Wed Sep 24, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"
, a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that the Board has named George O. Elston, 50, as Chief Financial Officer, effective October 1. He succeeds Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities. CBRX: 5.78 (+0.09)
